Patents by Inventor Robert MacLeod

Robert MacLeod has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MODULATORS OF FOXP3 EXPRESSION
    Publication number: 20230201243
    Abstract: The present embodiments provide methods, compounds, and compositions useful for inhibiting FOXP3 expression, which may be useful for treating, preventing, or ameliorating cancer.
    Type: Application
    Filed: November 29, 2022
    Publication date: June 29, 2023
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Alexey M. REVENKO, Robert A. MACLEOD, Susan M. FREIER
  • Modulation of Dystrophia Myotonica-Protein Kinase (DMPK) Expression
    Publication number: 20230174987
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of a DMPK mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for preferentially reducing CUGexp DMPK RNA, reducing myotonia or reducing spliceopathy in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate type 1 myotonic dystrophy, or a symptom thereof.
    Type: Application
    Filed: July 21, 2022
    Publication date: June 8, 2023
    Applicants: Ionis Pharmaceuticals, Inc., University of Rochester
    Inventors: C. Frank Bennett, Susan M. Freier, Robert A. MacLeod, Sanjay K. Pandey, Charles A. Thornton, Thurman Wheeler, Seng H. Cheng, Andrew Leger, Bruce M. Wentworth
  • Modulators of FOXP3 expression
    Patent number: 11547718
    Abstract: The present embodiments provide methods, compounds, and compositions useful for inhibiting FOXP3 expression, which may be useful for treating, preventing, or ameliorating cancer.
    Type: Grant
    Filed: November 14, 2019
    Date of Patent: January 10, 2023
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Alexey Revenko, Robert A. MacLeod, Susan M. Freier
  • MODULATORS OF YAP1 EXPRESSION
    Publication number: 20220315927
    Abstract: The present embodiments provide methods, compounds, and compositions useful for inhibiting YAP1 expression, which may be useful for treating, preventing, or ameliorating a cancer associated with YAP1.
    Type: Application
    Filed: November 16, 2021
    Publication date: October 6, 2022
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Youngsoo Kim, Xiaolin Luo, Robert MacLeod, Susan M. Freier, Huynh-Hoa Bui
  • MODULATORS OF IRF4 EXPRESSION
    Publication number: 20220241320
    Abstract: The present embodiments provide methods, compounds, and compositions useful for inhibiting IRF4 expression, which may be useful for treating, preventing, or ameliorating a cancer associated with IRF4.
    Type: Application
    Filed: December 17, 2021
    Publication date: August 4, 2022
    Inventors: Tianyuan ZHOU, Youngsoo KIM, Robert MACLEOD, Huynh-Hoa BUI, Susan M. FREIER
  • MODULATORS OF MALAT1 EXPRESSION
    Publication number: 20220243205
    Abstract: The present embodiments provide methods, compounds, and compositions useful for inhibiting MALAT1 expression, which may be useful for treating, preventing, or ameliorating a cancer associated with MALAT1.
    Type: Application
    Filed: February 8, 2022
    Publication date: August 4, 2022
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Susan M. FREIER, Youngsoo KIM, Robert MACLEOD
  • Modulators of EZH2 expression
    Patent number: 11365416
    Abstract: The present embodiments provide methods, compounds, and compositions useful for inhibiting EZH2 expression, which may be useful for treating, preventing, or ameliorating a cancer associated with EZH2.
    Type: Grant
    Filed: April 11, 2019
    Date of Patent: June 21, 2022
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Minji Jo, Youngsoo Kim, Robert MacLeod, Susan M. Freier
  • Modulators of MALAT1 expression
    Patent number: 11279932
    Abstract: The present embodiments provide methods, compounds, and compositions useful for inhibiting MALAT1 expression, which may be useful for treating, preventing, or ameliorating a cancer associated with MALAT1.
    Type: Grant
    Filed: February 27, 2020
    Date of Patent: March 22, 2022
    Assignee: IONIS PHARMACEUTICALS, INC.
    Inventors: Susan M. Freier, Youngsoo Kim, Robert MacLeod
  • Modulators of IRF4 expression
    Patent number: 11241451
    Abstract: The present embodiments provide methods, compounds, and compositions useful for inhibiting IRF4 expression, which may be useful for treating, preventing, or ameliorating a cancer associated with IRF4.
    Type: Grant
    Filed: March 1, 2019
    Date of Patent: February 8, 2022
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Tianyuan Zhou, Youngsoo Kim, Robert MacLeod, Huynh-Hoa Bui, Susan M. Freier
  • Modulators of YAP1 expression
    Patent number: 11214803
    Abstract: The present embodiments provide methods, compounds, and compositions useful for inhibiting YAP1 expression, which may be useful for treating, preventing, or ameliorating a cancer associated with YAP1.
    Type: Grant
    Filed: January 31, 2020
    Date of Patent: January 4, 2022
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Youngsoo Kim, Xiaolin Luo, Robert MacLeod, Susan M. Freier, Huynh-Hoa Bui
  • MODULATORS OF EZH2 EXPRESSION
    Publication number: 20210155935
    Abstract: The present embodiments provide methods, compounds, and compositions useful for inhibiting EZH2 expression, which may be useful for treating, preventing, or ameliorating a cancer associated with EZH2.
    Type: Application
    Filed: April 11, 2019
    Publication date: May 27, 2021
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Minji Jo, Youngsoo Kim, Robert MacLeod, Susan M. Freier
  • MODULATORS OF YAP1 EXPRESSION
    Publication number: 20210123059
    Abstract: The present embodiments provide methods, compounds, and compositions useful for inhibiting YAP1 expression, which may be useful for treating, preventing, or ameliorating a cancer associated with YAP1.
    Type: Application
    Filed: January 31, 2020
    Publication date: April 29, 2021
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Youngsoo Kim, Xiaolin Luo, Robert MacLeod, Susan M. Freier, Huynh-Hoa Bui
  • MODULATORS OF IRF4 EXPRESSION
    Publication number: 20210038631
    Abstract: The present embodiments provide methods, compounds, and compositions useful for inhibiting IRF4 expression, which may be useful for treating, preventing, or ameliorating a cancer associated with IRF4.
    Type: Application
    Filed: March 1, 2019
    Publication date: February 11, 2021
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Tianyuan Zhou, Youngsoo Kim, Robert MacLeod, Huynh-Hoa Bui, Susan M. Freier
  • MODULATION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 3 (STAT3) EXPRESSION
    Publication number: 20200385716
    Abstract: Disclosed herein are antisense compounds and methods for decreasing STAT3 mRNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate hyperproliferative diseases.
    Type: Application
    Filed: October 8, 2019
    Publication date: December 10, 2020
    Inventors: Eric E. SWAYZE, Susan M. FREIER, Robert A. MACLEOD, Youngsoo KIM
  • Modulation of Dystrophia Myotonica-Protein Kinase (DMPK) Expression
    Publication number: 20200362353
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of a DMPK mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for preferentially reducing CUGexp DMPK RNA, reducing myotonia or reducing spliceopathy in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate type 1 myotonic dystrophy, or a symptom thereof.
    Type: Application
    Filed: December 20, 2019
    Publication date: November 19, 2020
    Applicants: Ionis Pharmaceuticals, Inc., University of Rochester
    Inventors: C. Frank Bennett, Susan M. Freier, Robert A. MacLeod, Sanjay K. Pandey, Charles A. Thornton, Thurman Wheeler, Seng H. Cheng, Andrew Leger, Bruce M. Wentworth
  • MODULATORS OF MALAT1 EXPRESSION
    Publication number: 20200277604
    Abstract: The present embodiments provide methods, compounds, and compositions useful for inhibiting MALAT1 expression, which may be useful for treating, preventing, or ameliorating a cancer associated with MALAT1.
    Type: Application
    Filed: February 27, 2020
    Publication date: September 3, 2020
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Susan M. Freier, Youngsoo Kim, Robert MacLeod
  • MODULATORS OF FOXP3 EXPRESSION
    Publication number: 20200179435
    Abstract: The present embodiments provide methods, compounds, and compositions useful for inhibiting FOXP3 expression, which may be useful for treating, preventing, or ameliorating cancer.
    Type: Application
    Filed: November 14, 2019
    Publication date: June 11, 2020
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Alexey Revenko, Robert A. MacLeod, Susan M. Freier
  • Modulation of signal transducer and activator of transcription 3 (STAT3) expression
    Patent number: 10479993
    Abstract: Disclosed herein are antisense compounds and methods for decreasing STAT3 mRNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate hyperproliferative diseases.
    Type: Grant
    Filed: May 9, 2016
    Date of Patent: November 19, 2019
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Eric E. Swayze, Susan M. Freier, Robert A. MacLeod, Youngsoo Kim
  • MODULATORS OF KRAS EXPRESSION
    Publication number: 20180273577
    Abstract: The present embodiments provide methods, compounds, and compositions for inhibiting KRAS expression, which can be useful for treating, preventing, or ameliorating a disease associated with KRAS.
    Type: Application
    Filed: September 23, 2016
    Publication date: September 27, 2018
    Inventors: Alexey REVENKO, Susan M. FREIER, Robert A. MACLEOD
  • Modulation of androgen receptor expression
    Patent number: RE48461
    Abstract: Certain embodiments are directed to compounds and compositions targeted to human androgen receptor (AR) for inhibiting androgen receptor levels in a cell, which can be useful for methods of treating cancer and inhibiting cancer cell growth or proliferation.
    Type: Grant
    Filed: February 13, 2019
    Date of Patent: March 9, 2021
    Assignee: lonis Pharmaceuticals, Inc.
    Inventors: Robert A. Macleod, Youngsoo Kim, Tianyuan Zhou, Susan M. Freier, Punit Seth, Eric Swayze, Brett Monia